These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 46588)

  • 21. The progressive antithrombin (antithrombin-III, heparin-cofactor).
    Pálos LA
    Haematologia (Budap); 1974; 8(1-4):455-9. PubMed ID: 4461431
    [No Abstract]   [Full Text] [Related]  

  • 22. The proteinase inhibitor complexes (antithrombin III-thrombin, alpha 2antiplasmin-plasmin and alpha 1antitrypsin-elastase) in septicemia, fulminant hepatic failure and cardiac shock: value for diagnosis and therapy control in DIC/F syndrome.
    Egbring R; Seitz R; Blanke H; Leititis J; Kesper HJ; Burghard R; Fuchs G; Lerch L
    Behring Inst Mitt; 1986 Feb; (79):87-103. PubMed ID: 2424425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of hirudin on the consumption of antithrombin III in experimental DIC.
    Hauptmann J; Brüggener E
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):83-7. PubMed ID: 2459037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Actions and interactions of antithrombin and heparin.
    Rosenberg RD
    N Engl J Med; 1975 Jan; 292(3):146-51. PubMed ID: 127943
    [No Abstract]   [Full Text] [Related]  

  • 25. Fibrinolysis and fibrinogenolysis in disseminated intravascular coagulation.
    Takahashi H; Tatewaki W; Wada K; Niwano H; Shibata A
    Thromb Haemost; 1990 Jun; 63(3):340-4. PubMed ID: 2402738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antithrombin III assay using thrombin in disseminated intravascular coagulation (DIC), other thromboembolic disorders and hepatic diseases.
    Saxena V; Mishra DK; Subramanya H; Satyanarayana S; Sharma A
    Indian J Pathol Microbiol; 2004 Apr; 47(2):210-2. PubMed ID: 16295470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of heparin and/or antithrombin III in a model of disseminated intravascular coagulation induced by endotoxin in rabbits].
    Gómez C; Páramo JA; Rocha E
    Sangre (Barc); 1992 Feb; 37(1):5-10. PubMed ID: 1585238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Assay of plasma heparin and heparin-antithrombin III complex--studies in normal volunteers and thromboembolic patients].
    Oguma Y; Hasegawa H; Nagata H; Kawakami Y
    Rinsho Ketsueki; 1986 May; 27(5):723-9. PubMed ID: 3747167
    [No Abstract]   [Full Text] [Related]  

  • 29. Antithrombin III concentrates for treatment of disseminated intravascular coagulation in children.
    Hanada T; Abe T; Takita H
    Am J Pediatr Hematol Oncol; 1985; 7(1):3-8. PubMed ID: 4037242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of antithrombin III in patients with disseminated intravascular coagulation diagnosed by newly developed diagnostic criteria for critical illness.
    Sawamura A; Gando S; Hayakawa M; Hoshino H; Kubota N; Sugano M
    Clin Appl Thromb Hemost; 2009 Oct; 15(5):561-6. PubMed ID: 18840625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heparin cofactor and antithrombin.
    Abildgaard U
    Thromb Diath Haemorrh; 1975 Feb; 33(1):38-42. PubMed ID: 47193
    [No Abstract]   [Full Text] [Related]  

  • 32. [A new advance in theory of blood coagulation and fibrinolysis and its practical application].
    Matsuno K; Araki K
    Rinsho Byori; 1991 Feb; 39(2):179-84. PubMed ID: 1904112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical aspects of DIC--disseminated intravascular coagulation.
    Matsuda T
    Pol J Pharmacol; 1996; 48(1):73-5. PubMed ID: 9112631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical importance of the determination of antithrombin III by the use of a chromogenic substrate, in cases of disseminated intravascular coagulation and of acute hepatic insufficiency].
    Carmignoto F; Schivo P; Plebani M; Pengo V; Piccini P; Ceriotti G
    Quad Sclavo Diagn; 1981 Jun; 17(2):172-81. PubMed ID: 7267980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Decreased endothelial antithrombogenic activity in disseminated intravascular coagulation].
    Tsukasato T; Maruyama Y; Maruyama I
    Rinsho Ketsueki; 1987 Dec; 28(12):2110-6. PubMed ID: 2968472
    [No Abstract]   [Full Text] [Related]  

  • 36. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients.
    Wada H; Mori Y; Okabayashi K; Gabazza EC; Kushiya F; Watanabe M; Nishikawa M; Shiku H; Nobori T
    Am J Hematol; 2003 Jan; 72(1):1-7. PubMed ID: 12508260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Current views on the therapeutic use of heparin and antithrombin III in disseminated intravascular coagulation].
    Sobczyk J; Swietliński J; Podleśny-Owsińska T
    Pol Tyg Lek; 1989 Oct 2-16; 44(40-42):896-8. PubMed ID: 2487947
    [No Abstract]   [Full Text] [Related]  

  • 38. [Treatment of disseminated intravascular coagulation].
    Asakura H
    Rinsho Ketsueki; 1990 Jun; 31(6):756-62. PubMed ID: 2214166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Laboratory determination of heparin cofactor II.
    Ezenagu LC; Brandt JT
    Arch Pathol Lab Med; 1986 Dec; 110(12):1149-51. PubMed ID: 3778142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antithrombin II. Immunological and biological levels in hepatic cirrhosis and in disseminated intravascular coagulation (author's transl)].
    Barrantes A; Fonseca JE
    Sangre (Barc); 1979; 24(6):1043-7. PubMed ID: 538557
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.